Literature DB >> 11248789

Pharmacokinetics and pharmacodynamics of low-molecular-weight heparins and glycoprotein IIb/IIIa receptor antagonists in renal failure.

B S Smith1, P J Gandhi.   

Abstract

Data regarding the use of low-molecular-weight heparins (LMWHs) and glycoprotein (GP) IIb/IIIa receptor antagonists in patients with renal failure are limited. Renal failure has the potential to increase the risk of adverse drug events associated with LMWHs and GP IIb/IIIa receptor antagonists. This is due to changes in the pharmacokinetic and pharmacodynamic profiles of these agents in patients with renal failure. Until more data are available, clinicians should consider alternative therapies in this patient population.

Entities:  

Mesh：

Substances：

Year:  2001        PMID： 11248789     DOI： 10.1023/a:1008904310194

Source DB:  PubMed          Journal:  J Thromb Thrombolysis        ISSN： 0929-5305            Impact factor:   2.300


  50 in total

1.  Pharmacodynamics of CY 216 in healthy volunteers: inter-individual variations.

Authors:  M Rostin; J L Montastruc; G Houin; P D'Azemar; B Bayrou; B Boneu
Journal:  Fundam Clin Pharmacol       Date:  1990       Impact factor: 2.748

Review 2.  Low molecular weight heparins: practical considerations.

Authors:  C M Kessler
Journal:  Semin Hematol       Date:  1997-10       Impact factor: 3.851

3.  Bioavailability and antagonization of the low molecular weight heparin CY 216 in man.

Authors:  J Harenberg; B Würzner; R Zimmermann; G Schettler
Journal:  Thromb Res       Date:  1986-11-15       Impact factor: 3.944

4.  Randomised placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention: IMPACT-II. Integrilin to Minimise Platelet Aggregation and Coronary Thrombosis-II.

Authors: 
Journal:  Lancet       Date:  1997-05-17       Impact factor: 79.321

5.  Defective platelet aggregation in response to platelet-activating factor in uremia associated with low platelet thromboxane A2 generation.

Authors:  D Macconi; G Viganò; G Bisogno; M Galbusera; S Orisio; G Remuzzi; M Livio
Journal:  Am J Kidney Dis       Date:  1992-04       Impact factor: 8.860

6.  Bleeding in renal failure: altered platelet function in chronic uraemia only partially corrected by haemodialysis.

Authors:  G Remuzzi; M Livio; G Marchiaro; G Mecca; G de Gaetano
Journal:  Nephron       Date:  1978       Impact factor: 2.847

7.  Reversible activation defect of the platelet glycoprotein IIb-IIIa complex in patients with uremia.

Authors:  A Benigni; P Boccardo; M Galbusera; J Monteagudo; L De Marco; G Remuzzi; Z M Ruggeri
Journal:  Am J Kidney Dis       Date:  1993-11       Impact factor: 8.860

8.  Enhanced nitric oxide synthesis in uremia: implications for platelet dysfunction and dialysis hypotension.

Authors:  M Noris; A Benigni; P Boccardo; S Aiello; F Gaspari; M Todeschini; M Figliuzzi; G Remuzzi
Journal:  Kidney Int       Date:  1993-08       Impact factor: 10.612

9.  The antithrombotic activity and pharmacokinetics of enoxaparine, a low molecular weight heparin, in humans given single subcutaneous doses of 20 to 80 mg.

Authors:  A M Frydman; L Bara; Y Le Roux; M Woler; F Chauliac; M M Samama
Journal:  J Clin Pharmacol       Date:  1988-07       Impact factor: 3.126

10.  Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade.

Authors: 
Journal:  Lancet       Date:  1998-07-11       Impact factor: 79.321
View more
  6 in total

Review 1.  Antiplatelet drugs: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.

Authors:  John W Eikelboom; Jack Hirsh; Frederick A Spencer; Trevor P Baglin; Jeffrey I Weitz
Journal:  Chest       Date:  2012-02       Impact factor: 9.410

2.  [Clinical pharmacology of current antiplatelet drugs].

Authors:  D Trenk; T Nührenberg; C Stratz; C M Valina; W Hochholzer
Journal:  Herz       Date:  2014-11       Impact factor: 1.443

Review 3.  Emergency management of hemorrhagic complications in the era of glycoprotein IIb/IIIa receptor antagonists, clopidogrel, low molecular weight heparin, and third-generation fibrinolytic agents.

Authors:  Walter S Schroeder; Pritesh J Gandhi
Journal:  Curr Cardiol Rep       Date:  2003-07       Impact factor: 2.931

Review 4.  A systematic review on the accumulation of prophylactic dosages of low-molecular-weight heparins (LMWHs) in patients with renal insufficiency.

Authors:  Ferdows Atiq; Patricia M L A van den Bemt; Frank W G Leebeek; Teun van Gelder; Jorie Versmissen
Journal:  Eur J Clin Pharmacol       Date:  2015-06-14       Impact factor: 2.953

5.  Doxorubicin-induced vascular toxicity--targeting potential pathways may reduce procoagulant activity.

Authors:  Irit Ben Aharon; Hadas Bar Joseph; Moran Tzabari; Boris Shenkman; Nahid Farzam; Mattan Levi; Ruth Shalgi; Salomon M Stemmer; Naphtali Savion
Journal:  PLoS One       Date:  2013-09-20       Impact factor: 3.240

Review 6.  Pharmacokinetics of Toxin-Derived Peptide Drugs.

Authors:  David Stepensky
Journal:  Toxins (Basel)       Date:  2018-11-20       Impact factor: 4.546
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.